Associated Papers
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
A comprehensive benchmark for multiple highly efficient base editors with broad targeting scope.
Wang X et al.
Biorxiv : the Preprint Server for Biology, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
Anabtawi N et al.
Leukemia, 2025
Glioblastoma, IDH-Wildtype With Epithelioid Morphology and a BCR::NTRK2 Fusion.
Umeres-Francia GE et al.
International Journal of Surgical Pathology, 2025
Single-cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment.
Aertgeerts M et al.
Hemasphere, 2025
A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer.
Rangarajan A et al.
Frontiers in Oncology, 2025
Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations.
Gordon J et al.
Blood Cancer Journal, 2024
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.
Lap CJ et al.
Annals of Hematology, 2024
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML.
Macečková D et al.
Molecular Biology Reports, 2024
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
Mirza Z et al.
International Journal of Molecular Sciences, 2024
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
A Review of FLT3 Kinase Inhibitors in AML.
Negotei C et al.
Journal of Clinical Medicine, 2023
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
Ge SS et al.
British Journal of Haematology, 2023
Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.
Jensen CE et al.
Journal of Cellular and Molecular Medicine, 2022
Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy.
Chang YK et al.
International Journal of Molecular Sciences, 2022
Whole-exome sequencing reveals a comprehensive germline mutation landscape and identifies twelve novel predisposition genes in Chinese prostate cancer patients.
Liang Y et al.
Plos Genetics, 2022
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T et al.
Nature Communications, 2022
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T et al.
Nature Communications, 2022
Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD.
Stasik S et al.
Frontiers in Oncology, 2022
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.
Ribeiro S et al.
Cancers, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.
Li P et al.
Frontiers in Oncology, 2021
Common germline-somatic variant interactions in advanced urothelial cancer.
Vosoughi A et al.
Nature Communications, 2020
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.
Morita K et al.
Nature Communications, 2020
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Eguchi M et al.
Biomedicines, 2020
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H et al.
Cancer Science, 2020
High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage.
Borowczyk M et al.
Therapeutic Advances in Medical Oncology, 2020
First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.
Daver N et al.
Frontiers in Oncology, 2020
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.
Kennedy VE et al.
Frontiers in Oncology, 2020
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.
Yoshimi A et al.
Nature, 2019
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
Zhang H et al.
Nature Communications, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
The modular network structure of the mutational landscape of Acute Myeloid Leukemia.
Ibáñez M et al.
Plos One, 2018
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.
Messina M et al.
Oncotarget, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014